Trump/RFK Broker a Pharma Truce In Exchange for a Cheaper Drug Prices (Mark Cuban in Shambles)

By Stocks News   |   6 months ago   |   Stock Market News
Trump/RFK Broker a Pharma Truce In Exchange for a Cheaper Drug Prices (Mark Cuban in Shambles)

“Now I’m scared… I’m scared I’m gonna lose my job” -Mark Cuban, probably

To the absolute horror of Mark Cuban’s Cost Plus empire… Doctor Donnie and RFK Jr. have Big Pharma in a full-on chokehold. 

Because as of last night, Donald Trump locked in the final piece of his drug pricing blitz… cutting a deal with Regeneron Pharmaceuticals and wrapping up agreements with 17 major drugmakers. 

And somehow… it’s turned into a full Michael Scott win-win-win situation. 

Drug companies get a three-year pass on tariffs (including the threat of up to 100% import taxes)… and in return, they agree to slash prices and sell drugs at “most-favored nation” levels… aka what people in other rich countries are already paying.

You know… the prices Americans have been getting absolutely cooked on for years.

Because just to level-set… U.S. patients pay way more than everyone else. We’re talking up to 3x what other developed countries pay for the same drugs.

So naturally, the government looked at that and said, “Yeah… we’re not doing that anymore.” (I’m sure RFK wanted to nuke the whole system, but hey… he’ll take the consolation prize.) New Joe Rogan guest appearance coming soon.

Under the deal, Regeneron agreed to cut Medicaid prices on both current and future drugs… and drop the price of its cholesterol drug Praluent to $225 (down from $537).

They’re also rolling these drugs onto a new government platform called TrumpRx.gov… which still feels like a Shane Gillis SNL skit… but is apparently very real (here’s the website, it’s finally working).

And this isn’t some one-off handshake deal either… 

Seventeen companies (including Pfizer, Eli Lilly, and Amgen) have now signed on.

Together, they account for about 86% of the branded drug market in the U.S.

So this isn’t your average niche policy tweak… think of it as a full-on pricing reset attempt.

Looks like a clean win for the Donald Trump administration… which despite what they might admit, could use a little positive PR right about now. But, there’s always a but. Actually… several.

For starters, these deals mostly hit branded drugs… while more than

90% of prescriptions in the U.S. are generics. So yeah, it sounds massive (and for certain drugs, it is)… but this isn’t flipping the entire system overnight. 

Second… let’s not pretend these companies suddenly found religion overnight.

They’re getting bulletproof tariff protection, some regulatory breathing room, and a direct-to-consumer lane through the government.

So while they gave something up.

They’re definitely getting something back. 

And then there’s the bigger question… Can this actually hold?

Because pharma pricing has been one of the most complex, politically radioactive issues in the U.S. for decades… and every time Washington even thinks about pushing prices down, Big Pharma tends to remind them (real quick) who has the deepest pockets and the best lobbyists in the room.

Anyways… Mark Cuban is probably somewhere punching air right now as that Cost Plus edge starts looking a little less… exclusive.

At the time of publishing this article, Stocks.News doesn’t hold positions in companies mentioned in the article.

Did you find this insightful?

Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer